Life Sciences

Thursday, April 9, 2020

Life science founders are technical experts in their fields, but frequently fail to understand the needs of the stakeholders who will determine their path to market. This gap sends investors running, and all but ensures immediate or eventual company failure.

Join us on Thursday, April 9th, as Dr. Lucia Mokres breaks down the six major stakeholder categories relevant to most life science companies, and shares key strategies for closing the knowledge gap between founders and their market success. 

February 2020

Cancer is the biggest therapeutic area for licensing deals. But there are almost 3,000 drugs in Phase 1 through Phase 3, so competition for licensing deals and for market position is huge. Checkpoint inhibitors have benefits in most tumors and have made combination trials an industry standard. But everything in immuno-oncology has become...

December 2019

Interest in investing in healthcare services and technology companies is at unprecedented levels. Supported by enormous reserves of capital, large companies, private equity firms, and family offices are buying medical groups and healthcare...

November 2019

While ACTs have yet to score any major wins in solid tumors beyond the early success of TILs, many early-stage clinical programs are slated to readout within the next few years.

In this discussion, we asked a panel of experts their views on the most exciting new developments, what they seek to license...

June 2019

The human body and its microbiome live in a symbiotic relationship In this webinar, biopharma partnering expert and Life Sciences consultant, Linda Pullan, PhD, explores today’s oncology landscape and offered her perspective on trends, pipeline by indication, dealmaking, and the top ten...

Based on the web panel discussion on January 2019

Antibody-Drug Conjugates (ADC) combine the specificity of the antibody recognizing the antigen target, typically with the potent tumor-killing effects of a cytotoxic, attached typically via a linker to the antibody. Six ADCs have already been approved; sales are expected to be about $2b in 2018, growing to $12b by...

January 2019

Antibody-Drug Conjugates (ADC) combine the specificity of the antibody recognizing the antigen target, typically with the potent tumor-killing effects of a cytotoxic, attached typically via a linker to the antibody. Six ADCs have already been approved; sales are expected to be about $2b in 2018, growing to $12b by... 

December 2018

Precision medicine, which has been pioneered by the field of oncology, aims to target the right treatments to the right patients at the right time. Recent advances in genomics and imaging, as well as the discovery of other biomarkers, have enabled...

It’s not easy to go from a nascent scientific concept to a fully-funded life sciences organization. In this web panel discussion, the panelists discussed the best ways to navigate this path successfully. The discussion provided examples of how executive teams can partner business...

The clinical trial industry is highly regulated with a complex landscape. Contract Research Organizations (CROs) are a big part of any strategic product development life cycle. Sponsoring companies of new drugs, devices or biologics may outsource all or part of their clinical research.

August 2018

The clinical trial industry is highly regulated with a complex landscape. Contract Research Organizations (CROs) are a big part of any strategic product development life cycle. Sponsoring companies of new drugs, devices or biologics may outsource all or part of their clinical research...